Table 2. Characteristics of study participants by trial and age group.
| Variables | MiPPAD 1 N = 4,735 |
MiPPAD 2 N = 1,069 |
|||
|---|---|---|---|---|---|
| ≤19 years n = 1,101 (23.3%) |
>19 years n = 3,634 (76.7%) |
≤19 years n = 100 (9.4%) |
>19 years n = 969 (90.6%) |
||
| Demographic and baseline clinical data | |||||
| Age, years 1 | 17.5 (1.4) | 26.8 (5.4) | 17.9 (1.0) | 27.6 (5.1) | |
| Gravidity 2 | Primigravidae | 832 (75.6) | 541 (14.9) | 54 (54.0) | 54 (5.6) |
| Gestational age at recruitment, weeks 1 | 19.7 (5.2) | 20.4 (5.0) | 20.7 (4.7) | 20.0 (5.7) | |
| Anaemia 2 | <11 g/dL Hb | 701 (63.7) | 2,107 (58.0) | 73 (73.0) | 637 (65.7) |
| MUAC at baseline 2 | ≤ 22 cm | 140 (12.7) | 250 (6.9) | 2 (2.0) | 19 (2.0) |
| Literacy 2 | Illiterate | 154 (14.0) | 1,288 (35.4) | 15 (15.0) | 187 (19.3) |
| Adherent to treatment 2 * | Yes | 778 (70.7) | 2,654 (73.0) | 82 (82.0) | 776 (80.1) |
| Data origin | |||||
| HIV status 3 | Negative | 1,101 (23.3) | 3,634 (76.7) | - | - |
| Positive | - | - | 100 (9.4) | 969 (90.6) | |
| Study arm 3 | SP | 364 (23.1) | 1,211 (76.9) | - | - |
| MQ | 737 (23.3) | 2,423 (76.7) | 52 (9.7) | 482 (90.3) | |
| Placebo | - | - | 48 (9.0) | 487 (91.0) | |
| Country 3 | Mozambique | 463 (39.2) | 719 (60.8) | 65 (11.6) | 495 (88.4) |
| Gabon | 355 (30.2) | 819 (69.8) | - | - | |
| Tanzania | 162 (13.5) | 1,035 (86.5) | 2 (4.4) | 43 (95.6) | |
| Benin | 121 (10.2) | 1,061 (89.8) | - | - | |
| Kenya | - | - | 33 (7.1) | 431 (92.9) | |
1Arithmetic mean (standard deviation).
2n (column percentage).
3n (row percentage within each trial).
*Adherent to all intermittent preventive treatment doses, per protocol trial population.
Hb, hemoglobin; MiPPAD, Malaria in Pregnancy Preventive Alternative Drugs study; MQ, mefloquine; MUAC, mid-upper arm circumference; SP, sulfadoxine-pyrimethamine.